Literature DB >> 21685466

DNMT3A mutations are rare in childhood acute myeloid leukemia.

Felicitas Thol, Michael Heuser, Frederik Damm, Jan-Henning Klusmann, Katarina Reinhardt, Dirk Reinhardt.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21685466      PMCID： PMC3148921          DOI： 10.3324/haematol.2011.046839

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  12 in total

1.  CEBPalpha mutations in childhood acute myeloid leukemia.

Authors:  D-C Liang; L-Y Shih; C-F Huang; I-J Hung; C-P Yang; H-C Liu; T-H Jaing; L-Y Wang; W-H Chang
Journal:  Leukemia       Date:  2005-03       Impact factor: 11.528

2.  Incidence and prognostic influence of DNMT3A mutations in acute myeloid leukemia.

Authors:  Felicitas Thol; Frederik Damm; Andrea Lüdeking; Claudia Winschel; Katharina Wagner; Michael Morgan; Haiyang Yun; Gudrun Göhring; Brigitte Schlegelberger; Dieter Hoelzer; Michael Lübbert; Lothar Kanz; Walter Fiedler; Hartmut Kirchner; Gerhard Heil; Jürgen Krauter; Arnold Ganser; Michael Heuser
Journal:  J Clin Oncol       Date:  2011-06-13       Impact factor: 44.544

3.  CNS irradiation in pediatric acute myleoid leukemia: equal results by 12 or 18 Gy in studies AML-BFM98 and 2004.

Authors:  Ursula Creutzig; Martin Zimmermann; Jean-Pierre Bourquin; Michael N Dworzak; Gudrun Fleischhack; Christine von Neuhoff; Annette Sander; André Schrauder; Arend von Stackelberg; Joerg Ritter; Jan Starý; Dirk Reinhardt
Journal:  Pediatr Blood Cancer       Date:  2011-04-07       Impact factor: 3.167

4.  Less toxicity by optimizing chemotherapy, but not by addition of granulocyte colony-stimulating factor in children and adolescents with acute myeloid leukemia: results of AML-BFM 98.

Authors:  Ursula Creutzig; Martin Zimmermann; Thomas Lehrnbecher; Norbert Graf; Johann Hermann; Charlotte M Niemeyer; Alfred Reiter; Jörg Ritter; Michael Dworzak; Jan Stary; Dirk Reinhardt
Journal:  J Clin Oncol       Date:  2006-09-20       Impact factor: 44.544

5.  DNMT3A mutations in acute myeloid leukemia.

Authors:  Timothy J Ley; Li Ding; Matthew J Walter; Michael D McLellan; Tamara Lamprecht; David E Larson; Cyriac Kandoth; Jacqueline E Payton; Jack Baty; John Welch; Christopher C Harris; Cheryl F Lichti; R Reid Townsend; Robert S Fulton; David J Dooling; Daniel C Koboldt; Heather Schmidt; Qunyuan Zhang; John R Osborne; Ling Lin; Michelle O'Laughlin; Joshua F McMichael; Kim D Delehaunty; Sean D McGrath; Lucinda A Fulton; Vincent J Magrini; Tammi L Vickery; Jasreet Hundal; Lisa L Cook; Joshua J Conyers; Gary W Swift; Jerry P Reed; Patricia A Alldredge; Todd Wylie; Jason Walker; Joelle Kalicki; Mark A Watson; Sharon Heath; William D Shannon; Nobish Varghese; Rakesh Nagarajan; Peter Westervelt; Michael H Tomasson; Daniel C Link; Timothy A Graubert; John F DiPersio; Elaine R Mardis; Richard K Wilson
Journal:  N Engl J Med       Date:  2010-11-10       Impact factor: 91.245

6.  Clinical relevance of Wilms tumor 1 gene mutations in childhood acute myeloid leukemia.

Authors:  Iris H I M Hollink; Marry M van den Heuvel-Eibrink; Martin Zimmermann; Brian V Balgobind; Susan T C J M Arentsen-Peters; Marielle Alders; Andre Willasch; Gertjan J L Kaspers; Jan Trka; Andre Baruchel; Siebold S N de Graaf; Ursula Creutzig; Rob Pieters; Dirk Reinhardt; C Michel Zwaan
Journal:  Blood       Date:  2009-01-26       Impact factor: 22.113

7.  FLT3 mutations in childhood acute lymphoblastic leukemia.

Authors:  Scott A Armstrong; Meghann E Mabon; Lewis B Silverman; Aihong Li; John G Gribben; Edward A Fox; Stephen E Sallan; Stanley J Korsmeyer
Journal:  Blood       Date:  2003-12-11       Impact factor: 22.113

8.  Favorable prognostic impact of NPM1 gene mutations in childhood acute myeloid leukemia, with emphasis on cytogenetically normal AML.

Authors:  I H I M Hollink; C M Zwaan; M Zimmermann; T C J M Arentsen-Peters; R Pieters; J Cloos; G J L Kaspers; S S N de Graaf; J Harbott; U Creutzig; D Reinhardt; M M van den Heuvel-Eibrink; C Thiede
Journal:  Leukemia       Date:  2008-11-20       Impact factor: 11.528

9.  Prevalence and prognostic value of IDH1 and IDH2 mutations in childhood AML: a study of the AML-BFM and DCOG study groups.

Authors:  F Damm; F Thol; I Hollink; M Zimmermann; K Reinhardt; M M van den Heuvel-Eibrink; C M Zwaan; V de Haas; U Creutzig; J-H Klusmann; J Krauter; M Heuser; A Ganser; D Reinhardt; C Thiede
Journal:  Leukemia       Date:  2011-06-07       Impact factor: 12.883

10.  Leukemic mutations in the methylation-associated genes DNMT3A and IDH2 are rare events in pediatric AML: a report from the Children's Oncology Group.

Authors:  Phoenix A Ho; Matthew A Kutny; Todd A Alonzo; Robert B Gerbing; Jason Joaquin; Susana C Raimondi; Alan S Gamis; Soheil Meshinchi
Journal:  Pediatr Blood Cancer       Date:  2011-04-18       Impact factor: 3.838
View more
  10 in total

1.  Mutations in DNA methyltransferase (DNMT3A) observed in acute myeloid leukemia patients disrupt processive methylation.

Authors:  Celeste Holz-Schietinger; Doug M Matje; Norbert O Reich
Journal:  J Biol Chem       Date:  2012-06-21       Impact factor: 5.157

2.  DNA methyltransferase 3a hot-spot locus is not mutated in pediatric patients affected by acute myeloid or T-cell acute lymphoblastic leukemia: an Italian study.

Authors:  Maddalena Paganin; Martina Pigazzi; Silvia Bresolin; Riccardo Masetti; Franca Fagioli; Sabina Chiaretti; Giovanni Cazzaniga; Franco Locatelli; Andrea Pession; Geertruy te Kronnie; Giuseppe Basso
Journal:  Haematologica       Date:  2011-08-31       Impact factor: 9.941

Review 3.  DNMT3A in haematological malignancies.

Authors:  Liubin Yang; Rachel Rau; Margaret A Goodell
Journal:  Nat Rev Cancer       Date:  2015-02-19       Impact factor: 60.716

Review 4.  Molecular therapeutic approaches for pediatric acute myeloid leukemia.

Authors:  Sarah K Tasian; Jessica A Pollard; Richard Aplenc
Journal:  Front Oncol       Date:  2014-03-18       Impact factor: 6.244

5.  MGMT promoter methylation as a potential prognostic marker for acute leukemia.

Authors:  Dominika Sobieszkoda; Joanna Czech; Natalia Gablo; Marta Kopanska; Jacek Tabarkiewicz; Agnieszka Kolacinska; Tadeusz Robak; Izabela Zawlik
Journal:  Arch Med Sci       Date:  2017-10-31       Impact factor: 3.318

Review 6.  Gene Mutations as Emerging Biomarkers and Therapeutic Targets for Relapsed Acute Myeloid Leukemia.

Authors:  Habsah Aziz; Chow Y Ping; Hamidah Alias; Nurul-Syakima Ab Mutalib; Rahman Jamal
Journal:  Front Pharmacol       Date:  2017-12-07       Impact factor: 5.810

7.  Proviral Integration of Moloney Virus-2 (PIM-2) Expression Level as a Prognostic Marker in Patients with Acute Myeloid Leukemia.

Authors:  Gehad Hamed; Hisham M Omar; Abbas M Sarhan; Hossam E Salah
Journal:  Int J Gen Med       Date:  2022-04-20

8.  SWI/SNF Subunits SMARCA4, SMARCD2 and DPF2 Collaborate in MLL-Rearranged Leukaemia Maintenance.

Authors:  V Adam Cruickshank; Patrycja Sroczynska; Aditya Sankar; Satoru Miyagi; Carsten Friis Rundsten; Jens Vilstrup Johansen; Kristian Helin
Journal:  PLoS One       Date:  2015-11-16       Impact factor: 3.240

Review 9.  Genomic characterization of acute leukemias.

Authors:  Sabina Chiaretti; Valentina Gianfelici; Giulia Ceglie; Robin Foà
Journal:  Med Princ Pract       Date:  2014-06-20       Impact factor: 1.927

10.  DNMT3A mutations in Chinese childhood acute myeloid leukemia.

Authors:  Weijing Li; Lei Cui; Chao Gao; Shuguang Liu; Xiaoxi Zhao; Ruidong Zhang; Huyong Zheng; Minyuan Wu; Zhigang Li
Journal:  Medicine (Baltimore)       Date:  2017-08       Impact factor: 1.889
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.